Domvanalimab
As of the edition of 20 October 2026, Domvanalimab is an antibody: in active development; acts on TIGIT.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2030
- Kind
- Antibody
- Registered trials
- 22, 2 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Skin and connective tissue; Blood and lymph; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TIGIT | T-cell immunoreceptor with Ig and ITIM domains | Q495A1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 1 | 2 | 0 |
| Phase 2 | 16 | 1 | 12 | 2 |
| Phase 3 | 3 | 1 | 2 | 0 |
| All trials | 22 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2018 to now |
| Arcus Biosciences | Lead sponsor of trials | 2018 to now |
| Taiho | Lead sponsor of trials | 2021 to now |
| AstraZeneca | Lead sponsor of trials | 2022 to now |